Cat. No. | Product name | CAS No. |
DC65963 |
Acid-PEG5-C2-Boc
Featured
AAcid-PEG5-C2-Boc is a PEG derivative containing a t-butyl protected carboxyl group with a terminal carboxylic acid. The terminal carboxylic acid can be reacted with primary amine groups in the presence of activators (e.g. EDC, or DCC) to form a stable amide bond. The hydrophilic PEG spacer increases solubility in aqueous media. The t-butyl protected carboxyl group can be deprotected under acidic conditions. |
1309460-29-4 |
DC65964 | tert-Butyl 5-Hydroxypentanoate Featured | 91420-49-4 |
DC65965 |
Tri-GalNAc(OAc)3
Featured
Tri-GalNAc(OAc)3 is a triantenerrary N-acetylgalactosamine (tri-GalNAc) with an amino group, which is useful precursor for synthesis of GalNAc-LYTAC that engage the asialoglycoprotein receptor for targeted protein degradation. Tri-GalNAc(OAc)3 was first reported in Nat Chem Biol. 2021 Sep;17(9):937-946 (compound ). This product has no formal name at the moment. |
1159408-64-6 |
DC65966 |
DSPE-PEG2000-triGalNAc ammonium
Featured
DSPE-PEG2K-triGalNAc is a polar lipid composed of DSPE and tri-N-acetylgalactosamine that can be used to construct liposomes target to asialoglycoprotein receptor (ASGPR). |
2936651-86-2 |
DC60568 |
RMC-9805
Featured
RMC-9805 is a first-in-class, mutant-selective, covalent and orally bioavailable KRAS-G12D(ON) inhibitor. RMC-9805 exhibits direct anti-tumor effects and indirectly transformed the TME through inhibition of cancer cell-intrinsic KRAS-G12D oncogenic signaling. |
2922732-54-3 |
DC60569 |
ABBV-303
Featured
ABBV-303 is a novel c-Met targeted multispecific NK cell engager. ABBV-303 binding to NKG2D and CD16a results in redirection of both innate (NK cells) and adaptive (CD8+ T cells) immune cells to lyse c-Met expressing tumor cells. |
|
DC60570 |
ORIC-944
Featured
ORIC-944 is a potent, selective, allosteric inhibitor of PRC2 that binds the EED (Embryonic Ectoderm Development) subunit within the complex. ORIC-944 demonstrats single agent tumor growth inhibition in a spectrum of in vivo prostate cancer models, including AR-positive, AR-mutant, ARv7, ARPI-responsive and ARPI-resistant models. |
|
DC60571 |
BBO-8520
Featured
BBO-8520 is a first-in-class, direct covalent inhibitor of both KRAS-G12C (ON) and (OFF) states. BBO-8520 displays highly significant binding to KRAS-G12C in a global cysteine proteome analysis and is 100x more selective for KRAS-G12C than for WT-KRAS and other mutant isoforms, with no measurable activity against N- or H-RAS. |
|
DC60572 |
NST-628
Featured
NST-628 is a potent pan-RAF-MEK molecular glue that prevents phosphorylation and activation of MEK by RAF. NST-628 demonstrates broad efficacy in cellular and patient-derived, in vivo tumor models harboring KRAS, NRAS, BRAF class II/III, and NF1 mutations. |
|
DC60573 |
VVD-214 (RO7589831)
Featured
VVD-214 (RO7589831) is a synthetic lethal allosteric inhibitor of WRN helicase. VD-214 covalently engages cysteine 727 of WRN in a nucleotide cooperative manner and inhibits ATP hydrolysis and helicase activity, resulting in widespread double-stranded DNA breaks, nuclear swelling, and cell death in MSI-high, but not microsatellite stable cells. |
|
DC60574 |
RMC-6236
Featured
RMC-6236 is a first-in-class, potent, oral tri-complex RASMULTI(ON) small molecule inhibitor designed to treat cancers driven by a variety of RAS mutations. |
|
DC60575 |
U-101
Featured
U-101 is an ionizable lipid for mRNA delivery. U-101-LNP/IL-2F mRNA formulation demonstrats effective antitumor activity and safety.LNPs containing lipid U-101 and encapsulating mRNA encoding a fusion protein composed of IL-2, a linker, and CD25 inhibit tumor growth in an MC-38 mouse xenograft model. |
|
DC60576 |
AZD8421
Featured
AZD8421 is a highly selective CDK2 inhibitor with IC50 of 9 nM and shows selectivity over CDK1, CDK4 and CDK6. AZD8421 shows robust monotherapy activity in a CCNE1 amplified ovarian model OVCAR3 with regressions seen with monotherapy and in combination with palbociclib. |
|
DC65967 |
DBCO-PEG4-acid
Featured
DBCO-PEG4-acid is a PEG Linker. PEG Linkers may be useful in the development of antibody drug conjugates. |
1537170-85-6 |
DC60577 |
HC-7366
Featured
HC-7366 is an orally bioavailable and efficacious GCN2 (general control nonderepressible 2) kinase activator with IC50 of 12 nM. |
|
DC65968 |
Bz-(Me)Tz-NHS
Featured
Bz-(Me)Tz-NHS is a click chemistry reagent containing an methyltetrazine group. Bz-(Me)Tz-NHS is 3rd generation Click-Linker for Cu-free click conjugation. |
1454558-58-7 |
DC60578 |
TE-EP8-S
Featured
Lipid TE-EP8-S is a one-component ionizable cationic lipid for mRNA delivery to splenic T cells. |
|
DC60579 |
Lipid B3
Featured
Lipid B3 is a biodegradable ionizable lipid for liver targeted delivery. Lipid B3-LNP shows high delivery efficacy and low toxicity in delivering RNA to liver cells. |
|
DC65969 |
SUN 75856
Featured
SUN 75856, also known as N-trifluoroacetyl (TFA) protected aminolink C6 phosphoramidite for the synthesis of 5'-amino-modified oligonucleotides. TFA protection is smoothly removed during ammonia deprotection, and does not require any additional steps. If necessary, the resulting oligonucleotides can be purified by ion exchange chromatography, or gel electrophoresis. This product has no formal name at the moment. |
133975-85-6 |
DC60580 |
Endosidin5(ES5)
Featured
Endosidine 5 (ES5), is one of the most potent small molecules interferes with recycling endosomes through Annexin A6, thereby promoting the release and expression of mRNA into the cytoplasm. The delivered mRNAs is greatly enhanced via inhibition of endocytic recycling in cells and in live mice. NAV2729 (NAV) and endosidin 5 (ES5), resulted in significant enhancement (1.5–2 folds) of LNP-mediated delivery of Fluc mRNAs. Incubation of NAV and ES5 together caused modest further increases in Fluc expression in comparison to the sole application of either compound. |
|
DC65971 | (S)-5-(3-(heptyloxy)-5-(octan-2-yloxy)benzyloxy)isophthalic acid Featured | |
DC65972 | (R)-5-(3-(heptyloxy)-5-(octan-2-yloxy)benzyloxy)isophthalic acid Featured |